US EditionAkeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
- Akeso, Inc. announced the first patient has been enrolled in the Phase III clinical trial for ivonescimab in treating advanced metastatic colorectal cancer.
- This trial is a crucial initiative by Akeso to meet the worldwide unmet clinical need for advanced metastatic colorectal cancer treatment.
- Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related deaths.
- Professor Yanhong Deng presented promising Phase II efficacy data of ivonescimab combined with chemotherapy at the 2024 ESMO Congress.
Insights by Ground AI
Does this summary seem wrong?
54 Articles
54 Articles
Rutland Herald+53 Reposted by 53 other sources
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for…
Coverage Details
Total News Sources54
Leaning Left8Leaning Right4Center20Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 25%
C 63%
13%
Factuality
To view factuality data please Upgrade to Premium
